Clinical trial
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory…
NCT00003663 · Hoag Memorial Hospital Presbyterian, Other · Withdrawn
Key facts
| NCT number | NCT00003663 |
|---|---|
| Title | Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma |
| Official title | Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma |
| Lead sponsor | Hoag Memorial Hospital Presbyterian, Other |
| Collaborators | Cancer Biotherapy Research Group |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, dexamethasone |
| Enrollment | 0 |
| Start date | Jun 1, 1998 |
| Primary completion | Jan 1, 2000 |
| Completion | Jan 1, 2000 |
| First posted | Aug 4, 2004 |
| Last update posted | Aug 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: